News Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
77 ^JPY	0.00%		-1.28%	-37.90%

Apr. 15	Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	MT
Feb. 23	Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Modalis Announces updated strategic plan and business consolidation of US operation	Apr. 15	AQ
Modalis Announces Partnership with Ginkgo Bioworks	Apr. 15	AQ
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	Apr. 14	MT
Modalis Announces Partnership with Ginkgo Bioworks	Apr. 12	BU
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	Feb. 23	MT
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains	Dec. 13	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	Dec. 12	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	Dec. 12	CI
Modalis and JCR Pharmaceuticals enter into joint research agreement	Dec. 12	BU
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC	Nov. 29	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC	Nov. 06	CI
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023	23-09-27	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong Limited	23-09-10	CI
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc	23-08-07	CI
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development	23-06-25	CI
Modalis Therapeutics to Grant Stock Options	23-06-16	MT
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting	23-04-19	BU
Modalis Therapeutics Corporation to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of A Type of Muscular Dystrophy At the ASGCT Annual Meeting	23-04-19	CI
Modalis to Allot Stock Options	23-03-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Summary

Filters